Incident Stroke in Pediatric Sickle cell Anemia Despite Overall Improved Transcranial Doppler Velocity in a Ugandan Hydroxyurea Trial: Antecedent and ongoing risks
Rattachement africain : Ouganda, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Transcranial doppler ultrasound (TCD) screening for primary stroke prevention in children with sickle cell anemia (SCA) was established in higher-resource regions, targeting interventions for highest velocity ("abnormal"). We sought to identify additional stroke risk factors in Uganda. Methods: We conducted a 30-month open-label single-arm Ugandan hydroxyurea trial, dose-escalated to maximum tolerated dose, aimed to test brain protection for children aged 3-9 years with SCA. Study procedures included history, clinical stroke examination and prospective TCD and laboratory assessments. Results: Overall, 264 children received study HU, mean age 5.6±1.7, hemoglobin 7.8±1.2g/dL, fetal hemoglobin (HbF) 11.9±8.1%, enrolment TCD maximum velocity 148.4±29.3cm/second; 15 (5.7%) had abnormal TCD. Mean TAMV at trial completion was131.9±SD25.7 cm/sec. Four participants without abnormal enrolment TCD developed acute stroke within the initial 16 months (incidence 0.62 per 100 person years); Two had enrolment HbF ≤3.1%, 2 had low oxygen saturation (90%), 1 had recurring severe anemia necessitating multiple transfusions. Apparent stroke precipitants were severe malaria, acute chest syndrome, recent pain crisis or uncertain cause. At trial completion, 8 additional participants had a higher risk TCD category than at enrolment. Conclusion: Effectiveness of TCD screening for stroke prevention may vary by region, as no participant with incident stroke was at highest risk. Antecedent and/or ongoing SCA-related risks of anemia, low HbF, hypoxemia, infections and/or disease complications likely contributed to stroke despite trial HU. Results suggest that TCD alone may not fully identify highest stroke risk in the region, and need for primary stroke prevention from early and continuous hydroxyurea therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Incident Stroke in Pediatric Sickle cell Anemia Despite Overall Improved Transcranial Doppler Velocity in a Ugandan Hydroxyurea Trial: Antecedent and ongoing risks
- Date Crossref
- 29/01/2025
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
World Health Organization - Uganda Ouganda (code pays fourni par la source)Organisme public
-
Cincinnati Children's Hospital Medical Center Division of Hematology pays non établi dans la noticeÉtablissement de santé
-
Makerere University Dept. of Paediatrics and Child Health Makerere University, Ouganda (code pays fourni par la source)Université ou école supérieure
-
Columbia University Irving Medical Center pays non établi dans la noticeÉtablissement de santé
-
Global Health Uganda Kampala, Ouganda (pays nommé en fin d’affiliation)Institution
-
Columbia University Medical Center Dept. of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
World Health Organization - Uganda (Ouganda), Division of Hematology — Cincinnati Children's Hospital Medical Center et Dept. of Paediatrics and Child Health — Makerere University (Makerere University, Ouganda), avec 3 autres affiliations. Pays d’affiliation : Ouganda.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.